BLACK WEEKSViales −15% · kits −10% · resto −5%con el códigoEnvío gratis en Alemania a partir de 200 €

Esta página se ha traducido automáticamente y puede contener errores. ¿Eres hablante nativo? Nos encantaría recibir tus comentarios y correcciones.Enviar comentarios

The Peptide Desk The Peptide Desk
Reta + Cagri Blend, foto del producto
GLP-1

Reta + Cagri Blend

GLP-1

  • Envío desde Alemania

Pedido

Precio unitario - Envío gratis en Alemania a partir de 200 € durante las Black Weeks
  • DHL con seguimiento
  • Embalaje discreto

4.6 de 5 en Trustpilot73 reseñas

De un vistazo

Reta + Cagri Blend en cifras

Las cifras clave de nuestra enciclopedia.

Entrada completa de la enciclopedia
Class
Triple agonistGLP-1 / GIP / glucagon, + amylin analog
Half-life
Retatrutide around 6 dayscagrilintide around 7 to 8 days
Form
Lyophilisatepowder, reconstituted with BAC water
Sizes
30 mg1 size in the shop

Todavía no hay ningún análisis de laboratorio de Reta + Cagri Blend. Vota por élHazlo analizar tú mismo, pagamos la mitadTodos los análisis de laboratorio

Conocimiento

Todo sobre Reta + Cagri Blend

Conviene tenerlo

Lo que necesitas con ello

El agua bacteriostática se añade automáticamente a tu carrito. Jeringas y toallitas con un clic.

Jeringas de insulina

10 uds. · 5.50 €

Toallitas con alcohol

50 uds. · 10 €

¿Cuánta agua?

Unidades en la jeringa para tu tamaño de vial.

Abrir calculadora →

FAQ

Preguntas frecuentes

Fuentes de cada respuesta: entrada de la enciclopedia

¿Aún tienes alguna pregunta?

Escríbenos, nuestro equipo te ayudará.

Is the Reta + Cagri Blend approved or studied?

No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and cagrilintide together. Both components are in phase 3 and not approved.

Why Retatrutide and cagrilintide together?

Both act on different satiety pathways: Retatrutide on GLP-1, GIP and glucagon, cagrilintide on amylin receptors. With semaglutide as the partner, weight loss in a phase 1b trial after 20 weeks was 17.1 instead of 9.8 percent. For Retatrutide as the partner there are no data.

What do the studies of the components show?

Retatrutide alone: in TRIUMPH-1 after 80 weeks 25.0 percent less body weight on average at the highest study dose, 3.9 percent on placebo. Cagrilintide alone: up to 10.8 percent after 26 weeks in phase 2, 3.0 percent on placebo. In a substudy liver fat also fell sharply on Retatrutide.

Why is the cagrilintide share so small?

The vial contains five times as much Retatrutide as cagrilintide, because Retatrutide is the stronger and limiting part. Anyone going by the Retatrutide share stays far below the amounts used in the cagrilintide trials. Whether the small share contributes anything has not been studied.

How long do the components stay in the body?

Retatrutide had a half-life of about six days in a phase 1b study, cagrilintide 159 to 195 hours in another study, so about a week. Both fit one dose per week.

Which side effects were seen with the components?

With both, mainly gastrointestinal effects such as nausea and diarrhoea, depending on the dose. On Retatrutide heart rate rose in a dose-dependent way in phase 2. Two satiety signals together may strengthen nausea at the start, this has not been measured for this blend.

Which trials are still running?

Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The RENEW trials of cagrilintide alone run until 2027. No trial of the blend is listed in the registry.

Relacionados

Productos relacionados